Literature DB >> 18638556

Rodent genetic models of Huntington disease.

Mary Y Heng1, Peter J Detloff, Roger L Albin.   

Abstract

Huntington disease (HD) is a dominantly inherited human neurodegenerative disorder characterized by motor deficits, cognitive impairment, and psychiatric symptoms leading to inexorable decline and death. Since the identification of the huntingtin gene and the characteristic expanded CAG repeat/polyglutamine mutation, multiple murine genetic models and one rat genetic model have been generated. These models fall into two general categories: transgenic models with ectopic expression of the characteristic expanded CAG codon mutation, and knock-in models with expression of mutant huntingtin under control of endogenous regulatory elements. Rodent genetic models are valuable tools for studying mechanisms of pathogenesis in HD and for preclinical evaluation of possible therapies. In this mini-review, we provide a concise comparative summary of rodent genetic models of HD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638556     DOI: 10.1016/j.nbd.2008.06.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  74 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

Review 3.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

Review 4.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

5.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

6.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

Review 7.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 8.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

Review 9.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

10.  Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis.

Authors:  Guohao Wang; Xudong Liu; Marta A Gaertig; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.